Next Article in Journal
Recent Applications of Three Dimensional Printing in Cardiovascular Medicine
Next Article in Special Issue
Immunolocalization of Keratan Sulfate in Rat Spinal Tissues Using the Keratanase Generated BKS-1(+) Neoepitope: Correlation of Expression Patterns with the Class II SLRPs, Lumican and Keratocan
Previous Article in Journal
Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling
Previous Article in Special Issue
Fluorinated Galactoses Inhibit Galactose-1-Phosphate Uridyltransferase and Metabolically Induce Galactosemia-like Phenotypes in HEK-293 Cells
Open AccessReview

O-acetylated Gangliosides as Targets for Cancer Immunotherapy

UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, CNRS, Université de Lille, F-59000 Lille, France
OGD2 Pharma, Institut de Recherche en Santé de l’Université de Nantes, 44007 Nantes, France
Institut pour la Recherche sur le Cancer de Lille – IRCL – Place de Verdun, F-59000 Lille, France
Author to whom correspondence should be addressed.
Cells 2020, 9(3), 741;
Received: 27 February 2020 / Revised: 16 March 2020 / Accepted: 16 March 2020 / Published: 17 March 2020
(This article belongs to the Special Issue Glycosylation and Cell Biology)
O-acetylation of sialic acid residues is one of the main modifications of gangliosides, and modulates ganglioside functions. O-acetylation of gangliosides is dependent on sialyl-O-acetyltransferases and sialyl-O-acetyl-esterase activities. CAS1 Domain-Containing Protein 1 (CASD1) is the only human sialyl-O-acetyltransferases (SOAT) described until now. O-acetylated ganglioside species are mainly expressed during embryonic development and in the central nervous system in healthy adults, but are re-expressed during cancer development and are considered as markers of cancers of neuroectodermal origin. However, the specific biological roles of O-acetylated gangliosides in developing and malignant tissues have not been extensively studied, mostly because of the requirement of specific approaches and tools for sample preparation and analysis. In this review, we summarize our current knowledge of ganglioside biosynthesis and expression in normal and pathological conditions, of ganglioside O-acetylation analysis and expression in cancers, and of the possible use of O-acetylated gangliosides as targets for cancer immunotherapy. View Full-Text
Keywords: ganglioside; sialic acid; O-acetylation; sialate O-acetyltransferase; neuroectoderm derived cancer; immunotherapy ganglioside; sialic acid; O-acetylation; sialate O-acetyltransferase; neuroectoderm derived cancer; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Cavdarli, S.; Delannoy, P.; Groux-Degroote, S. O-acetylated Gangliosides as Targets for Cancer Immunotherapy. Cells 2020, 9, 741.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop